CCTU-Core

Quick facts

Phase 2 pipeline

• Active JNJ-54175446 · Diabetes
  JNJ-54175446 is a small molecule that targets the SGLT2 receptor.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• CCTU-Core portfolio CI brief
• CCTU-Core pipeline updates RSS